• (05 May 2021) Molnupiravir- was well tolerated at 400, 600 or 800mg doses with no severe adverse events

  May 27, 2021

  Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a phase 1, dose-escalating, randomised controlled study https://www.medrxiv.org/content/10.1101/2021.05.03.21256309v1  NCT04746183 – Of 103 volunteers screened, 18 participants were enrolled between 17 July and 30 October 2020. Molnupiravir was well tolerated… Continue reading "(05 May 2021) Molnupiravir- was well tolerated at 400, 600 or 800mg doses with no severe adverse events"

• (14 Dec 2020) Molnupiravir- 93.3% of adverse events were mild

  December 17, 2020

  Human Safety, Tolerability, and Pharmacokinetics of a Novel Broad-Spectrum Oral Antiviral Compound, Molnupiravir, with Activity Against SARS-CoV-2 https://www.medrxiv.org/content/10.1101/2020.12.10.20235747v1 Single and multiple doses of molnupiravir were evaluated in this first-in-human, phase 1 (NCT04392219), randomized, double-blind, placebo-controlled study in healthy volunteers, which… Continue reading "(14 Dec 2020) Molnupiravir- 93.3% of adverse events were mild"